AstraZeneca Signs Agentic AI Deal With Owkin for Research Automation

AstraZeneca has signed a three-year licensing agreement with French AI biotech company Owkin to deploy agentic artificial intelligence tools across parts of its research and competitive intelligence operations.

The deal gives AstraZeneca access to Owkin’s K Pro platform, which the company describes as an “AI Scientist” system designed to analyze scientific, clinical, and competitive datasets for pharmaceutical teams. According to Owkin’s announcement, the platform will be integrated into AstraZeneca’s internal IT systems and decision-making workflows. Financial terms were not disclosed.

Owkin said it will also build custom AI agents for AstraZeneca that can automate portions of research analysis and clinical intelligence tasks. The agreement was announced on May 13.

The partnership adds to a growing wave of pharmaceutical companies deploying autonomous or semi-autonomous AI systems inside research operations. That includes efforts around autonomous lab research systems and broader experimentation with AI-driven scientific workflows.

AI Agents Expand Beyond Research Copilots

Owkin said one of the custom agents being developed for AstraZeneca focuses on competitive intelligence. The system is designed to analyze clinical trial activity tied to specific targets or compounds, including patient recruitment trends, expected outcomes, and patent activity.

The company said the tools can support clinical trial planning and internal strategy decisions by synthesizing large volumes of scientific and operational data. Owkin’s infrastructure draws from multimodal patient datasets sourced through a network of more than 800 hospitals.

Thomas Clozel, CEO and Co-founder of Owkin, said in the company’s announcement that “the future of the pharmaceutical industry is agentic.”

Owkin has been expanding its broader “biology super intelligence” strategy around biological reasoning models and interoperable AI agents for life sciences research.

The agreement also builds on previous collaboration between AstraZeneca and Owkin around an AI-powered screening tool for inherited BRCA breast cancer mutations. Fierce Biotech first reported the latest licensing agreement on May 13.

Pharma Companies Accelerate Enterprise AI Investments

The AstraZeneca agreement comes as pharmaceutical companies increase investments in enterprise AI systems for drug discovery, clinical development, and operational planning.

AstraZeneca has publicly tied AI investments to its long-term growth targets. In a previous corporate update, the company said technology and data science initiatives would support its goal of reaching $80 billion in annual revenue by 2030.

The company has also expanded its internal AI infrastructure through additional oncology and foundation model initiatives.

Other pharmaceutical companies have recently announced similar AI partnerships. Bristol Myers Squibb partnered with Faro Health on AI-assisted clinical trial protocol design, while Novo Nordisk and Merck announced enterprise AI partnerships with OpenAI and Google, respectively. Eli Lilly and NVIDIA also unveiled a dedicated supercomputer initiative for drug discovery earlier this year, part of a broader push toward AI-driven drug discovery infrastructure.

The latest AstraZeneca deployment reflects a broader shift from experimental AI copilots toward operational AI systems embedded directly into pharmaceutical research and decision workflows.